RemeGen (HKG:9995, SHA:688331) returned to profit in 2025, swinging year on year to a net profit attributable to owners of 708.5 million yuan, or 1.29 yuan per share, according to a Hong Kong filing disclosure on Saturday.

The biopharmaceutical company's Hong Kong shares slumped less than 6%, while Shanghai shares fell less than 3% during Monday's midday trade.

The attributable loss a year earlier was 1.47 billion yuan, or 2.73 yuan per share.

Total operating revenue jumped 89% to 3.25 billion yuan from 1.72 billion yuan in the previous year.